

GBR 12935

Catalog No: tcsc3131



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

76778-22-8

Formula:

$C_{28}H_{34}N_2O$

Pathway:

Neuronal Signaling

Target:

Dopamine Transporter

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

414.58

Product Description


GBR 12935 is a potent, and selective dopamine reuptake inhibitor.

IC50 value:

Target: dopamine reuptake inhibitor

in vitro: The calculated K_d of [3H]GBR-12935 binding to CYP2D6 was 42.2 nM, indicating that GBR-12935 has a high affinity for CYP2D6. The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine) [1]. Co-perfusion of 100 microM GBR 12909 or GBR 12935 with either 100 microM sulpiride or raclopride produced a significant reduction in the GBR 12909 or GBR 12935 induced increase in the extracellular levels of dopamine to basal levels. In vitro, GBR 12909 (1-9 nM) dose-dependently inhibited active uptake of [3H]dopamine in homogenates of the nucleus accumbens [2].

in vivo: GBR 12935 elevated locomotion to a greater extent in C57BL/6J mice at the maximally active dose of 10 mg/kg. Locomotor stimulation by GBR 12935 remained consistent in both strains with repeated injections. DBA/2J mice became sensitized to cocaine-induced stereotypy with repeated injections. Cocaine induced no stereotypy in C57BL/6J mice on any test day. No stereotypies were induced by GBR 12935 in either strain on any test day [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!